Terumo to distribute Biocompatibles' Bead Block:
This article was originally published in Clinica
Executive Summary
UK device company Biocompatibles International has signed an exclusive global distribution deal for its PVA microsphere, Bead Block, which is used in embolisation therapy to block blood flow to tumours or vascular malformations. The agreement extends an existing partnership under which Terumo was appointed European distributor of the product in March. Terumo's worldwide sales of interventional products totalled $290m in fiscal 2003. Biocompatibles recently declared it had overcome manufacturing problems for Bead Block, although it admitted the product was really a stepping stone on the way to exploiting the bead technology in drug delivery applications (see Clinica No 1074, p 16).
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.